Live Blog

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Among sectoral indices, the Nifty Pharma index ended over 3 per cent higher led by rise in the shares of Sun Pharmaceutical Industries and Lupin.

SI Reporter New Delhi
markets, stocks, sensex, nifty, bse, nse
Photo: Shutterstock

Last Updated : Aug 14 2018 | 3:53 PM IST

3:49 PM

Nifty Pharma index ends 3.21% higher. Top gainers:

COMPANY LATEST PREV CLOSE GAIN(
)
GAIN(%)
SUN PHARMA.INDS. 601.80 563.90 37.90 6.72
BIOCON 589.40 571.70 17.70 3.10
DIVI'S LAB. 1154.55 1120.20 34.35 3.07
LUPIN 836.75 811.95 24.80 3.05
CIPLA 642.75 628.30 14.45 2.30

3:37 PM

Nifty sectoral gainers and losers

3:35 PM

BSE Sensex: Sun Pharma, YES Bank, RIL among top gainers of the day

3:33 PM

Market at close

The S&P BSE Sensex ended at 37,852, up 207 points while the broader Nifty50 index settled at 11,435, up 79 points.

3:12 PM

External factors, selective intervention by RBI led to rupee's fall: Garg

The government on Tuesday blamed "external factors" for the rupee's fall to an all-time low against the US dollar and said there is nothing to worry. Economic Affairs Secretary Subhash Chander Garg said external factors may ease going forward. READ MORE

3:02 PM

Sun Pharma rallies 7% as Q1 profit beats Street estimates

Shares of Sun Pharmaceutical Industries have rallied 7% to Rs 600 per share on the BSE after the pharmaceutical company reported a better-than-expected consolidated net profit at Rs 9.83 billion in June quarter (Q1FY19). The company had posted a loss of Rs 4.25 billion in the same quarter year ago. READ MORE

2:44 PM

MCX to launch rubber futures on Aug 16

Leading commodity bourse MCX today announced launching of the rubber futures from August 16 to provide hedging to the entire value chain in the rubber industry. The MCX said it will offer four futures contracts in rubber with each ending September, October, November and December, respectively, an official statement said. READ MORE

2:30 PM

Sebi's consent route to ease pending case load yields success in FY18
 
Markets regulator Securities and Exchange Board of India (Sebi) settled double the number of cases through the so-called consent mechanism in 2017-18, compared to the previous fiscal. According to data, Sebi resolved 200 cases through the consent route last fiscal as against 103 in 2016-17.
 
The amount earned by Sebi as settlement fees also saw a more than two-fold increase to Rs 300 million in FY18, compared to Rs 135 million in FY17. READ MORE

2:15 PM

STOCK ALERT Cadila Healthcare nears 52-week low post June quarter results
 
Shares of Cadila Healthcare have slipped 5% to Rs 336 per share, extending their 6% decline on Monday on the BSE, after the company reported a lower-than-expected 30% year on year (YoY) growth in net sales at Rs 28.94 billion in the June quarter (Q1FY19) due to lower US sales.
 
The company’s net profit grew by 233% YoY to Rs 4.60 billion in Q1FY19 due to other income of Rs 1.01 billion. READ MORE

2:00 PM

Market Check

INDEX LATEST PREVIOUS CHANGE CHANGE(%)
NIFTY 50 11439.80 11355.75 84.05 0.74
NIFTY 500 9718.75 9656.50 62.25 0.64
NIFTY MIDCAP 100 19114.50 19012.40 102.10 0.54
NIFTY SMALL 100 7473.65 7463.65 10.00 0.13
INDIA VIX 13.23 13.40 -0.17 -1.27
> More on NSE Indices

1:46 PM

COMMENT Aditi Nayar, Principal economist, ICRA on rupee, inflation

As expected, a favourable base effect for primary food items and minerals, dampened the WPI inflation to 5.1% in July 2018 from 5.8% in June 2018, mirroring the extent of the correction displayed by the CPI inflation print.

Contagion related to the crisis in Turkey has seeped into other emerging market currencies, causing the INR to depreciate as well. Factors such as broader emerging market currency movement, dollar strength, and the trend in crude oil prices will drive the outlook for the INR in the immediate term, which will have an impact on the landed cost of imports as well as various commodity prices, thereby transmitting into the WPI inflation.

Given the prevailing risk aversion in the global markets, the rupee is expected to remain volatile going ahead, and average 68.5/USD in FY2019

1:43 PM

MARKET COMMENT Sharekhan on rupee hitting 70 per dollar

Turkey crisis has triggered risk of trade leading to strengthening of US Dollar against all major currencies, especially, emerging market currencies. INR has relatively seen higher depreciation due to concerns related to fiscal slippages and dependence on imports for energy requirements. Going ahead, in the near term, we see scope for further pressure on INR despite the expected intervention by RBI.
 
Strategy for equity investors: We expect weakness in INR to be sentimentally positive for IT Services, select auto ancillaries and other export-driven companies. On the other hand, it would be negative for import dependent sectors including oil marketing companies and global commodities like metals

1:43 PM

PVR's acquisition of SPI Cinemas: Benefits offset high deal valuations

The Rs 6.33 billion price for a 71.7 per cent stake in SPI Cinemas enhances PVR’s pan-India presence, especially South India, where it had weak presence. Though South India accounts for half of India’s multiplex screens, it accounted for only 26 per cent of PVR’s overall portfolio. READ MORE

1:29 PM

Where is the rupee headed? Experts weigh in

Rupee hit a record low of 70 to the US dollar, making it the worst currency in the Asian region thus far in calendar year 2018 (CY18). The fall comes on the back of Turkey-led sell-off over the past few sessions. READ MORE

1:14 PM

IT shares extend gains; TCS, Infosys hit new highs

Shares of information technology (IT) companies were trading higher for the third straight day due to persisting weakness in the rupee. The rupee hit an all-time low of 70.08 against US dollar on Tuesday. READ MORE

First Published: Aug 14 2018 | 8:15 AM IST